Logo
x

Search

Subscribe Now

Infants

Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

  • April 15, 2021
Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

  • September 28, 2020
Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

  • April 28, 2020
Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

  • January 23, 2020
Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to

Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to

  • December 11, 2019
Vertex's Kalydeco (ivacaftor) Receives FDA's Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months

Vertex's Kalydeco (ivacaftor) Receives FDA's Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months

  • May 1, 2019
Pfizer’s Abrysvo (bivalent RSV prefusion F vaccine) Receives the US FDA’s Approval for the Prevention of Respiratory Syncytial Virus in Infants

    Pfizer’s Abrysvo (bivalent RSV prefusion F vaccine) Receives the US FDA’s Approval for the Prevention of Respiratory Syncytial Vir...

    • August 22, 2023
    AstraZeneca and Sanofi’s Beyfortus (nirsevimab) Receive the US FDA’s Approval for the Prevention of RSV Lower Respiratory Tract Disease in Infants

      AstraZeneca and Sanofi’s Beyfortus (nirsevimab) Receive the US FDA’s Approval for the Prevention of RSV Lower Respiratory Tract Di...

      • July 19, 2023
      Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)

        Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Res...

        • November 9, 2022
        Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

          Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

          • April 15, 2021
          Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

            Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

            • September 28, 2020
            Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

              Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

              • April 28, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.